Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.46 USD | -1.84% | +11.87% | +44.49% |
May. 02 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
Apr. 30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Business Summary
Number of employees: 55
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Matthew Robinson
CTO | Chief Tech/Sci/R&D Officer | 55 | 16-02-29 |
Jack Higgins
CTO | Chief Tech/Sci/R&D Officer | 45 | 23-10-01 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 16-12-31 |
Robert Lapetina
AUD | Comptroller/Controller/Auditor | 49 | 21-04-30 |
Bruce Turner
PRN | Corporate Officer/Principal | 60 | 23-10-01 |
Sandra Stoneman
LAW | General Counsel | 51 | 20-12-09 |
Kinney Horn
PRN | Corporate Officer/Principal | 49 | Jan. 31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 16-12-31 |
James Boylan
BRD | Director/Board Member | 57 | 23-10-01 |
Isaac Barchas
BRD | Director/Board Member | 56 | 23-10-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,943,368 | 49,138,414 ( 81.97 %) | 0 | 81.97 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.93% | 944M | |
+8.88% | 105B | |
-1.29% | 104B | |
+5.79% | 22.94B | |
-12.67% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-10.18% | 16.96B | |
+7.72% | 14.16B | |
+39.45% | 12.63B |
- Stock Market
- Equities
- IMNM Stock
- Company Immunome, Inc.